Franklin Genomic Advancements ETF (HELX) Institutional Ownership $30.08 +0.01 (+0.04%) Closing price 02/21/2025 03:55 PM EasternExtended Trading$30.08 0.00 (0.00%) As of 02/21/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartHoldingsOwnershipRatings Institutional Ownership Changes (13F Filings) for Franklin Genomic Advancements ETF (BATS:HELX)Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$1.55MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$11.56K Get HELX Insider Trade Alerts Want to know when executives and insiders are buying or selling Franklin Genomic Advancements ETF stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data HELX Institutional Buying and Selling by Quarter Franklin Genomic Advancements ETF Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025 Citadel Advisors LLC7,966$230K0.0%N/A2.655% 2/14/2025 Jane Street Group LLC41,030$1.18M0.0%N/A13.677% 2/11/2025 LPL Financial LLC16,965$489K0.0%+19.5%5.655% 2/5/2025 Halbert Hargrove Global Advisors LLC1,801$52K0.0%N/A0.600% 7/31/2024 Commonwealth Equity Services LLC6,677$212K0.0%-5.2%2.226% 1/26/2023Vigilant Capital Management LLC900$27K0.0%N/A0.000% (Data available from 1/1/2016 forward) HELX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of HELX shares? During the previous two years, the following institutional investors and hedge funds held shares of Franklin Genomic Advancements ETF shares: Jane Street Group LLC ($1.18M), LPL Financial LLC ($489K), Citadel Advisors LLC ($230K), and Commonwealth Equity Services LLC ($212K), Halbert Hargrove Global Advisors LLC ($52K).Learn more on HELX's institutional investors. Which institutional investors have been buying Franklin Genomic Advancements ETF stock? The following institutional investors have purchased Franklin Genomic Advancements ETF stock in the last 24 months: Jane Street Group LLC ($41.03K), Citadel Advisors LLC ($7.97K), LPL Financial LLC ($2.77K), and Halbert Hargrove Global Advisors LLC ($1.80K). How much institutional buying is happening at Franklin Genomic Advancements ETF? Institutional investors have bought a total of 53,565 shares in the last 24 months. This purchase volume represents approximately $1.55M in transactions. Which Franklin Genomic Advancements ETF major shareholders have been selling company stock? The following institutional investors have sold Franklin Genomic Advancements ETF stock in the last 24 months: Commonwealth Equity Services LLC ($365.00). How much institutional selling is happening at Franklin Genomic Advancements ETF? Institutional investors have sold a total of 365 shares in the last 24 months. This volume of shares sold represents approximately $11.56K in transactions. Related Companies BTEK Major Shareholders IBOT Major Shareholders ACT Major Shareholders IVRA Major Shareholders SATO Major Shareholders FSBD Major Shareholders EQRR Major Shareholders JCHI Major Shareholders LOPP Major Shareholders MNTL Major Shareholders This page (BATS:HELX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
